Avacta Group PLC (GB:AVCT)
LSE:AVCT
Want to see GB:AVCT full AI Analyst Report?
Top Page
Avacta Group plc
(LSE:AVCT)
Select Model
Select Model
Rating:50Neutral
Price Target:
79.00 p
▲(21.54% Upside)
Action:Reiterated
Date:05/26/26
The score is held down primarily by weak financial performance (ongoing losses, cash burn, and balance-sheet pressure). Technicals provide moderate support with price above longer-term averages and a positive MACD, while valuation remains challenged due to negative earnings and no dividend. The earnings call adds some offsetting strength from clinical progress and improved cash management, but near-term financing/partnering dependency and timeline risks remain material.
Positive Factors
Preclinical differentiation vs ADCs
Material preclinical advantages (much higher tumor Cmax and improved tumor:plasma selectivity) represent a durable technical moat. If translated clinically, this can materially improve therapeutic index, lower off-target toxicity, and make Avacta's platform more attractive to partners across many solid tumor indications.
Negative Factors
Weak cash flow & shrinking balance sheet
Persistent negative operating and free cash flows, combined with a materially reduced equity base and asset shrinkage, constrain financial flexibility. Limited runway increases dependency on external funding or partnering and raises execution and dilution risk for multi-year clinical programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Preclinical differentiation vs ADCs
Material preclinical advantages (much higher tumor Cmax and improved tumor:plasma selectivity) represent a durable technical moat. If translated clinically, this can materially improve therapeutic index, lower off-target toxicity, and make Avacta's platform more attractive to partners across many solid tumor indications.
Read all positive factors
Avacta Group plc (AVCT) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£345.55M
Dividend YieldN/A
Average Volume (3M)3.07M
Price to Earnings (P/E)―
Beta (1Y)0.90
Revenue GrowthN/A
EPS GrowthN/A
CountryUK
Employees154
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.09
Shares Outstanding440,415,500
10 Day Avg. Volume4,236,507
30 Day Avg. Volume3,069,625
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)93.68
Price to Sales (P/S)2052.69
P/FCF Ratio-9.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.06
Revenue Forecast (FY)N/A
Avacta Group plc Business Overview & Revenue Model
Company Description
Avacta Group plc is a biotechnology company based in the UK that focuses on developing innovative therapies and diagnostics for various diseases, including cancer. The company operates primarily in the life sciences sector, utilizing its proprieta...
How the Company Makes Money
Avacta makes money primarily through (1) collaboration and partnering income and (2) product and service revenues from its diagnostics-related activities, with additional potential upside from future commercialisation of therapeutics if/when candi...
Avacta Group plc Earnings Call Summary
Earnings Call Date:May 19, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Oct 05, 2026
Earnings Call Sentiment Positive
The call presented multiple important positive developments: on-time clinical execution (first-in-human dosing for AVA6103), promising preclinical metrics (up to ~40x tumor Cmax and ~3x tumor selectivity), strengthened IP, focused R&D investment (+31.5% YoY), cost reductions and a successful recent fundraising that extends runway into early Q1 2027. Offsetting these positives are meaningful near-term financing and timeline risks — limited cash runway without partner income, dependence on partnership to launch pivotal studies, tolerability/dose-selection questions at higher AVA6000 doses, and delays/hold status for the Affimer program. On balance the call emphasized substantive scientific and clinical progress alongside manageable but material financing and timing risks.Positive Updates
Clinical Milestone — AVA6103 First Patient Dosed
First patient dosed in FOCUS-01 Phase I (AVA6103) on time in March 2026; multicenter US-focused trial enrolling 6 advanced cancers with initial clinical data committed by end of 2026 (late Q4).
Negative Updates
Limited Near-Term Cash Runway and Financing Dependency
Cash balance of GBP 16.4m provides runway only into early Q1 2027 assuming no partnering income; company did not disclose monthly burn and remains dependent on further financing or partnerships to fund clinical development beyond that point.
Read all updates
Q4-2025 Updates
Positive
Negative
Clinical Milestone — AVA6103 First Patient Dosed
First patient dosed in FOCUS-01 Phase I (AVA6103) on time in March 2026; multicenter US-focused trial enrolling 6 advanced cancers with initial clinical data committed by end of 2026 (late Q4).
Read all positive updates
Company Guidance
The call guided a busy 2026 timetable and detailed financial and clinical metrics: R&D spend was GBP 18.8m in FY2025 (up from GBP 14.3m), administrative costs ~GBP 10m (down from GBP 12m), net operating cash outflow GBP 22.64m (vs GBP 24.94m in 2024), and the company has raised GBP 32.5m over the last 18 months (including an oversubscribed GBP 10m placing), leaving cash of GBP 16.4m at end-April 2026 and a runway into early Q1 2027 (assumes no partnering income). Clinically, AVA6103 (FOCUS‑01) dosed its first patient on time in March 2026, is enrolling across ~7–9 U.S. Phase Ia sites for six advanced tumor types (no UK centers), and initial Phase I data are expected by end‑2026 (late Q4); AVA6000 continues in Phase Ia/Ib with a recommended dose for expansion of 310 mg/m2 (other cohorts: 385, 385/200, 250) and Phase Ib/efficacy and cardiac‑safety data to be presented H1 2026 (ASCO/BIO). Pipeline timing also includes AVA6207 payload disclosures targeted in Q3 2026 and candidate selection in H2 2026; preclinical metrics cited include up to 40x higher tumor Cmax for released exatecan versus daruxtecan and ~3x higher tumor selectivity index versus ADCs, and the platform targets FAP expressed in ~90% of solid tumors.Avacta Group plc Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
27
Negative
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 113.00K | 113.00K | 2.85M | 9.65M | 2.94M |
| Gross Profit | -1.17M | 113.00K | 2.84M | 4.23M | -2.50M |
| EBITDA | -28.96M | -17.62M | -14.12M | -34.78M | -26.69M |
| Net Income | -38.38M | -52.84M | -24.95M | -36.94M | -26.32M |
Balance Sheet | |||||
| Total Assets | 29.42M | 48.27M | 73.19M | 92.65M | 47.00M |
| Cash, Cash Equivalents and Short-Term Investments | 16.86M | 12.87M | 16.63M | 41.78M | 26.19M |
| Total Debt | 14.92M | 22.93M | 23.51M | 62.94M | 1.70M |
| Total Liabilities | 26.94M | 38.99M | 51.39M | 74.21M | 5.78M |
| Stockholders Equity | 2.48M | 9.28M | 21.80M | 18.44M | 41.22M |
Cash Flow | |||||
| Free Cash Flow | -24.80M | -23.94M | -16.13M | -17.03M | -21.82M |
| Operating Cash Flow | -24.75M | -23.60M | -14.87M | -16.43M | -20.51M |
| Investing Cash Flow | 9.90M | -1.43M | -9.00M | -25.04M | 18.70M |
| Financing Cash Flow | 13.61M | 26.09M | -1.30M | 56.90M | 232.00K |
Avacta Group plc Technical Analysis
Positive
65.00
Price Trends
74.38
Positive
67.09
Positive
66.03
Positive
Market Momentum
0.83
Positive
51.35
Neutral
15.24
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:AVCT, the sentiment is Positive. The current price of 65 is below the 20-day moving average (MA) of 80.41, below the 50-day MA of 74.38, and below the 200-day MA of 66.03, indicating a neutral trend. The MACD of 0.83 indicates Positive momentum. The RSI at 51.35 is Neutral, neither overbought nor oversold. The STOCH value of 15.24 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:AVCT.
Avacta Group plc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | £337.86M | -0.40 | -31.83% | ― | -5.89% | -310.69% | |
53 Neutral | £248.03M | -44.99 | 90.29% | ― | ― | 69.01% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £345.55M | -8.99 | -2929.47% | ― | ― | ― | |
46 Neutral | £24.92M | 37.53 | -197.54% | ― | 3.31% | 21.91% | |
44 Neutral | £5.35M | -4.35 | -153.80% | ― | ― | 93.02% | |
43 Neutral | £81.68M | -4.85 | -116.21% | ― | 81.46% | -15.88% |
* Healthcare Sector Average
GB:AVCT
Avacta Group plc
79.00
42.00
113.51%
GB:NFX
Nuformix Plc
0.21
0.10
89.81%
GB:PRTC
PureTech Health
138.80
0.80
0.58%
GB:SCLP
Scancell Holdings
23.90
13.90
139.00%
GB:4BB
4basebio UK Societas
527.50
-582.50
-52.48%
GB:AREC
Arecor Therapeutics PLC
66.00
22.50
51.72%
Avacta Group plc Corporate Events
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and FinancingProduct-Related Announcements
Avacta advances pre|CISION oncology pipeline and extends cash runway into 2027
Positive
May 19, 2026
Avacta reported significant RD progress in 2025, advancing three generations of its pre|CISION platform, with AVA6000 and AVA6103 now in clinical development and AVA6207 moving through preclinical dual-payload work. The company highlighted encoura...
Business Operations and StrategyPrivate Placements and Financing
Avacta Cuts Convertible Debt with New Share Issue on AIM
Neutral
May 13, 2026
Avacta Group plc, a clinical-stage biopharmaceutical company specializing in tumor-activated oncology therapies through its proprietary pre|CISION platform, is developing peptide drug conjugates intended to deliver potent cancer drugs directly to ...
Business Operations and StrategyFinancial Disclosures
Avacta Sets Date for FY25 Results and Investor Presentation
Neutral
May 13, 2026
Avacta Therapeutics, a clinical-stage biopharmaceutical arm of Avacta Group plc, is developing its proprietary pre|CISION tumor-activated delivery platform to improve the safety and efficacy of highly potent cancer therapies. Its pipeline is led b...
Business Operations and StrategyProduct-Related Announcements
Avacta Showcases Pre|CISION Platform Data Beating Leading ADCs at 2026 Science Day
Positive
May 6, 2026
Avacta Group’s oncology-focused Avacta Therapeutics unit is advancing its proprietary pre|CISION tumor-activated drug delivery platform, which uses FAP-mediated activation to release potent chemotherapeutic payloads directly in tumors. The c...
Business Operations and StrategyRegulatory Filings and Compliance
Avacta Files Six‑Monthly Block Listing Update for Employee Share Schemes
Neutral
Apr 28, 2026
Avacta Group plc has reported its latest six‑monthly block listing return for employee share schemes, detailing movements in securities under its EMI and LTIP/ESOS plans. Under the EMI scheme, unallotted securities fell from 124,558 to 68,44...
Business Operations and StrategyProduct-Related Announcements
Avacta highlights tumor-targeted drug delivery gains as AVA6103 enters Phase 1
Positive
Apr 21, 2026
Avacta Group plc reported new data at the American Association for Cancer Research 2026 meeting that bolster the profile of its pre|CISION oncology delivery platform and its second clinical candidate, AVA6103. Updated preclinical analyses show AVA...
Business Operations and Strategy
Avacta CEO Named In Vivo Rising Leader as Oncology Platform Advances
Positive
Apr 14, 2026
Avacta Therapeutics, a clinical-stage oncology-focused biopharmaceutical company, is developing its proprietary pre|CISION® peptide drug conjugate platform to expand the reach of highly potent cancer therapies. Its pipeline includes the Gen O...
Business Operations and StrategyPrivate Placements and FinancingProduct-Related Announcements
Avacta advances pre|CISION oncology pipeline and extends cash runway with £10m raise
Positive
Apr 9, 2026
Avacta reported a strong start to 2026, with the U.S. IND for its Gen Two candidate AVA6103 cleared in January and the first patient dosed in the FOCUS-01 Phase 1 trial by the end of March. Preclinical data showed AVA6103’s sustained-release...
Business Operations and Strategy
Avacta to Showcase Next Chapter of pre|CISION Platform at 2026 Science Day
Positive
Apr 8, 2026
Avacta Therapeutics, the clinical-stage biopharmaceutical arm of Avacta Group plc, specializes in oncology-focused life sciences and is developing its proprietary pre|CISION tumor-activated delivery platform for peptide drug conjugates that target...
Business Operations and StrategyPrivate Placements and FinancingProduct-Related Announcements
Avacta doses first patient in Phase 1 trial of new tumor-activated cancer drug AVA6103
Positive
Mar 31, 2026
Avacta has begun dosing patients in its FOCUS-01 Phase 1 clinical trial of FAP-Exd (AVA6103), a Gen Two pre|CISION-based exatecan peptide drug conjugate, in adults with selected advanced solid tumors at three specialist U.S. oncology centers. Supp...
Private Placements and Financing
Avacta Raises £10m in Oversubscribed Share Placing and Director Subscription
Positive
Mar 27, 2026
Avacta Group plc has conditionally raised £10 million via an oversubscribed placing and director subscription of new ordinary shares at 63 pence each, representing about 3.6% of its existing share capital. The funds were raised through the is...
Business Operations and StrategyPrivate Placements and Financing
Avacta launches £10m equity raise to extend runway and advance oncology pipeline
Positive
Mar 26, 2026
Avacta Group plc plans to raise approximately £10 million through a discounted equity placing and subscription of around 15.9 million new shares at 63 pence, with Zeus Capital acting as sole bookrunner. The net proceeds are expected to fund r...
Business Operations and StrategyPrivate Placements and Financing
Avacta raises £10m to extend runway and advance oncology pipeline
Positive
Mar 26, 2026
Avacta Group plc has launched a £10 million equity fundraise via an accelerated placing of around 15 million new shares and a subscription for approximately 0.9 million shares at 63 pence, a 9.35% discount to the prior close. The proceeds are...
Business Operations and StrategyProduct-Related Announcements
Avacta to Present New pre|CISION Cancer Drug Conjugate Data at 2026 AACR
Positive
Mar 17, 2026
Avacta Therapeutics will showcase two preclinical and translational studies of its pre|CISION tumor-activated oncology platform at the 2026 American Association for Cancer Research meeting in San Diego. The presentations center on fibroblast activ...
Business Operations and StrategyProduct-Related Announcements
Avacta opens Phase 1 trial for sustained-release tumor-targeted exatecan therapy
Positive
Mar 16, 2026
Avacta Therapeutics has opened a Phase 1 trial for FAP-Exd (AVA6103), its second clinical program and first sustained-release pre|CISION peptide-drug conjugate, at specialty oncology centers in Virginia and Texas. The investigational therapy is a ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.